eiger inc is a research company located in 500 crescent ct ste 300, dallas, texas, united states.
Company profile
Ticker
EIGRQ
Exchange
Website
CEO
David Cory
Employees
Incorporated
Location
Fiscal year end
Sector
Industry (SIC)
Amgen • Gilead Sciences • Biogen • Qiagen • Moderna • Acorda Therapeutics • BioNTech SE • Sana Biotechnology • Ginkgo Bioworks • Bio-Techne ...
Former names
Celladon Corp
SEC CIK
Corporate docs
Subsidiaries
EBPI Merger, Inc. • EB Pharma LLC • Eiger BioPharmaceuticals Europe Limited • EigerBio Europe Limited ...
IRS number
330971591
EIGRQ stock data
Latest filings (excl ownership)
8-K
Entry into a Material Definitive Agreement
2 Aug 24
8-K
Regulation FD Disclosure
1 Aug 24
8-K
Regulation FD Disclosure
16 Jul 24
8-K
Completion of Acquisition or Disposition of Assets
10 Jul 24
8-K
Regulation FD Disclosure
1 Jul 24
8-K
Entry into a Material Definitive Agreement
21 Jun 24
8-K
Entry into a Material Definitive Agreement
14 Jun 24
8-K
Regulation FD Disclosure
28 May 24
8-K
Completion of Acquisition or Disposition of Assets
8 May 24
8-K
Departure of Directors or Certain Officers
2 May 24
Transcripts
EIGRQ
Earnings call transcript
2022 Q3
4 Nov 22
EIGRQ
Earnings call transcript
2022 Q2
7 Aug 22
EIGRQ
Earnings call transcript
2022 Q1
8 May 22
EIGRQ
Earnings call transcript
2021 Q4
11 Mar 22
EIGRQ
Earnings call transcript
2021 Q3
5 Nov 21
EIGRQ
Earnings call transcript
2021 Q2
8 Aug 21
EIGRQ
Earnings call transcript
2021 Q1
9 May 21
Latest ownership filings
SC 13D/A
Arkin Moshe
1 Jul 24
SC 13G/A
AMERIPRISE FINANCIAL INC
10 May 24
SC 13G/A
683 Capital Management, LLC
14 Feb 24
SC 13G/A
AMERIPRISE FINANCIAL INC
14 Feb 24
SC 13D/A
Arkin Moshe
4 Dec 23
SC 13D
Arkin Moshe
24 Nov 23
SC 13D/A
Propel Bio Management, LLC
2 Nov 23
4
RICHARD A KAYNE
2 Nov 23
4
LEEN KAWAS
2 Nov 23
3
RICHARD A KAYNE
30 Oct 23
Financial summary
Quarter (USD) | Dec 23 | Sep 23 | Jun 23 | Mar 23 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 23 | Dec 22 | Dec 21 | Dec 20 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 25.44 mm | 25.44 mm | 25.44 mm | 25.44 mm | 25.44 mm | 25.44 mm |
Cash burn (monthly) | 687.00 k | 29.83 k | 4.48 mm | 6.25 mm | 4.65 mm | 6.21 mm |
Cash used (since last report) | 5.32 mm | 230.94 k | 34.71 mm | 48.35 mm | 36.01 mm | 48.09 mm |
Cash remaining | 20.12 mm | 25.21 mm | -9.27 mm | -22.91 mm | -10.57 mm | -22.65 mm |
Runway (months of cash) | 29.3 | 845.0 | -2.1 | -3.7 | -2.3 | -3.6 |
Institutional ownership, Q2 2024
63.5% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 2 |
Opened positions | 0 |
Closed positions | 2 |
Increased positions | 0 |
Reduced positions | 0 |
13F shares | Current |
---|---|
Total value | 13.47 mm |
Total shares | 939.59 k |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Interwest Partners X | 935.43 k | $13.45 mm |
Vivo Ventures VI | 4.17 k | $22.00 k |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
2 Nov 23 | Kayne Richard A | Common Stock | Buy | Acquire P | Yes | No | 0.2977 | 23,398 | 6.97 k | 5,375,225 |
1 Nov 23 | Kayne Richard A | Common Stock | Buy | Acquire P | Yes | No | 0.2797 | 100,000 | 27.97 k | 5,351,827 |
31 Oct 23 | Leen Kawas | Common Stock | Buy | Acquire P | Yes | No | 0.2615 | 12,345 | 3.23 k | 4,391,432 |
31 Oct 23 | Leen Kawas | Common Stock | Buy | Acquire P | Yes | No | 0.2625 | 11,987 | 3.15 k | 4,379,087 |
31 Oct 23 | Kayne Richard A | Common Stock | Buy | Acquire P | Yes | No | 0.2414 | 130,509 | 31.50 k | 5,251,827 |
31 Oct 23 | Kayne Richard A | Common Stock | Buy | Acquire P | Yes | No | 0.2615 | 12,345 | 3.23 k | 5,121,318 |
31 Oct 23 | Kayne Richard A | Common Stock | Buy | Acquire P | Yes | No | 0.2625 | 11,987 | 3.15 k | 5,108,973 |
31 Aug 23 | Ingrid Choong | Stock Option Common Stock | Grant | Acquire A | No | No | 0.864 | 54,000 | 46.66 k | 54,000 |